ins018_055
Idiopathic Pulmonary Fibrosis (IPF)
InSilico Medicine Hong Kong LimitedPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
110 Active assets in the Idiopathic Pulmonary Fibrosis (IPF) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pirfenidone Endeavor Biomedicines, Inc. | Phase 4 | A |
N-Acetyl-L-Cysteine Endeavor Biomedicines, Inc. | Phase 4 | BBB |
Nintedanib Mannkind Corporation | Phase 4 | BBB |
Nerandomilast Boehringer Ingelheim | Phase 3 | BB |
hsk44459 Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →